BCAL Diagnostics

BCAL Diagnostics EBIT per Employee

EBIT per Employee of BCAL Diagnostics (BDX.AX) as of Oct 17, 2026.

EBIT per Employee

-AUD

Last updated:

EBIT per Employee of BCAL Diagnostics is 2026 - AUD. EBIT per Employee of BCAL Diagnostics was 2025 - AUD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

On Eulerpool you can find the complete historical development of EBIT per Employee BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's BCAL Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — BCAL Diagnostics

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — BCAL Diagnostics